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background: Early studies showed beneficial effects of phosphodiesterase 5 inhibitors (PDE5i) on cardiovascular function, but the RELAX trial 
observed no improvement in exercise capacity in patients with heart failure and preserved ejection fraction (HFpEF). We performed a prospective 
RELAX sub-study measuring left and right ventricular (LV, RV) function and arterial function.
Methods: A subgroup of participants in the RELAX trial (n=48, 69±8 years old, 58% women) underwent echocardiography at baseline and after 
treatment with sildenafil or placebo for 24 weeks. LV contractility was assessed by peak power index (PWR/EDV) and stroke work index (SW/EDV). 
RV systolic function was assessed by the RV myocardial performance index (MPI). LV afterload was assessed by arterial elastance (Ea) and RV 
afterload by pulmonary artery systolic pressure (PASP).
results: Compared with placebo (n=25), sildenafil (n=23) decreased Ea but did not alter LV volumes, mass, or EF (Table). In contrast, load-
independent indices of LV contractility were reduced by 10-15% with sildenafil. While PASP did not change, RV function improved with sildenafil 
(lower MPI values better).
conclusions: Among subjects with HFpEF, sildenafil treatment was associated with modest impairment in resting LV contractility despite beneficial 
effects on RV function and LV afterload. These offsetting effects on ventricular-vascular function may partially explain the lack of clinical benefit from 
PDE5i observed in the RELAX trial.
 
